The estimated Net Worth of Stephen Mitchener is at least $615 Thousand dollars as of 28 February 2023. Mr. Mitchener owns over 6,357 units of Axcella Health Inc stock worth over $587,674 and over the last 5 years he sold AXLA stock worth over $27,505. In addition, he makes $0 as Senior Vice President and Chief Business Officer at Axcella Health Inc.
Stephen has made over 4 trades of the Axcella Health Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 6,357 units of AXLA stock worth $19,262 on 28 February 2023.
The largest trade he's ever made was selling 6,357 units of Axcella Health Inc stock on 28 February 2023 worth over $19,262. On average, Stephen trades about 1,269 units every 91 days since 2019. As of 28 February 2023 he still owns at least 128,313 units of Axcella Health Inc stock.
You can see the complete history of Mr. Mitchener stock trades at the bottom of the page.
Stephen Mitchener Pharm.D. serves as Senior Vice President, Chief Business Officer of the Company. Prior to joining us, Dr. Mitchener served in increasing roles of responsibility at Novartis Pharmaceuticals Corporation from April 2005 to August 2018, most recently as Head of U.S. Oncology Strategy, Partnering and Operations. He previously served as a board observer for COTA Healthcare on behalf of Novartis Oncology.
Stephen Mitchener is 41, he's been the Senior Vice President and Chief Business Officer of Axcella Health Inc since . There are 16 older and 1 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.
Stephen's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.
Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa..., and Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
Axcella Health Inc executives and other stock owners filed with the SEC include: